Andrea Giaccari

List of Publications by Year
in descending order

99 papers	3,125 citations	159573 30 h-index	168376 53 g-index
101 all docs	101 docs citations	101 times ranked	5348 citing authors

#	Article	IF	Citations
1	Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an <scp>ITAS</scp> post hoc analysis. Diabetes, Obesity and Metabolism, 2022, 24, 327-331.	4.4	2
2	All-cause mortality and cardiovascular events in patients with type 2 diabetes treated with alpha-glucosidase inhibitors: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 511-514.	2.6	5
3	SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice. International Journal of Cardiology, 2022, 351, 66-70.	1.7	9
4	Italian guidelines for the treatment of type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 770-814.	2.6	10
5	Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 529-536.	2.6	7
6	Effects of insulin on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	2.6	4
7	Italian guidelines for the treatment of type 2 diabetes. Acta Diabetologica, 2022, 59, 579-622.	2.5	13
8	Physiciansâ€™ misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes. Cardiovascular Diabetology, 2022, 21, 57.	6.8	10
9	SGLT2i Increase Endogenous Glucose Production: Thatâ€™s Good News!. Diabetes Care, 2022, 45, 1301-1302.	8.6	1
10	Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 699-704.	2.6	26
11	Noradrenergic fibers are associated with beta-cell dedifferentiation and impaired beta-cell function in humans. Metabolism: Clinical and Experimental, 2021, 114, 154414.	3.4	12
12	Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. Diabetes and Vascular Disease Research, 2021, 18, 147916412199592.	2.0	5
13	Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS. Acta Diabetologica, 2021, 58, 789-796.	2.5	0
14	Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?. Diabetes Care, 2021, 44, 647-654.	8.6	31
15	A Systematic Comparison of Protocols for Recovery of High-Quality RNA from Human Islets Extracted by Laser Capture Microdissection. Biomolecules, 2021, 11, 625.	4.0	5
16	Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial. Diabetes Therapy, 2021, 12, 2101-2113.	2.5	6
17	Pancreaticoduodenectomy model demonstrates a fundamental role of dysfunctional Î² cells in predicting diabetes. Journal of Clinical Investigation, 2021, 131, .	8.2	21
18	Prediabetes: how pathophysiology drives potential intervention on a subclinical disease with feared clinical consequences. Minerva Endocrinology, 2021, 46, 272-292.	1.1	4

#	Article	IF	Citations
19	Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2745-2755.	2.6	21
20	A novel low-density lipoprotein receptor variant in a Ukrainian patient: a case report and overview of the disease-causing low-density lipoprotein receptor variants associated to familial hypercholesterolemia. Molecular Biology Reports, 2021, , 1.	2.3	1
21	Real-world outcomes of treatment with insulin glargine 300â€‰U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. Current Medical Research and Opinion, 2020, 36, 571-581.	1.9	12
22	Postoperative hyperglycemia affects survival after gastrectomy for cancer: A single-center analysis using propensity score matching. Surgery, 2020, 167, 815-820.	1.9	10
23	Endocrine and Metabolic Insights from Pancreatic Surgery. Trends in Endocrinology and Metabolism, 2020, 31, 760-772.	7.1	18
24	Galectin-3 gene deletion results in defective adipose tissue maturation and impaired insulin sensitivity and glucose homeostasis. Scientific Reports, 2020, 10, 20070.	3.3	6
25	Sotagliflozin added to optimized insulin therapy leads to <scp>HbA1c</scp> reduction without weight gain in adults with type 1 diabetes: A pooled analysis of <scp>inTandem1</scp> and <scp>inTandem2</scp>. Diabetes, Obesity and Metabolism, 2020, 22, 2089-2096.	4.4	9
26	Comparable efficacy with similarly low risk of hypoglycaemia in patientâ€•vs physicianâ€•managed basal insulin initiation and titration in insulinâ€•naÃ¯ve type 2 diabetic subjects: The Italian Titration Approach Study. Diabetes/Metabolism Research and Reviews, 2020, 36, e3304.	4.0	11
27	Diabetes Secondary to Pancreatic Diseases. Endocrinology, 2020, , 523-539.	0.1	1
28	1100-P: Efficacy and Safety of Sotagliflozin by Baseline Renal Function in Adults with Type 1 Diabetes. Diabetes, 2020, 69, .	0.6	1
29	1795-P: Proinsulin-Insulin Pancreatic Islets In-situ Expression Mirrors Metabolic Defects Observed in Type 2 Diabetic and Glucose Intolerant Living Donors. Diabetes, 2020, 69, 1795-P.	0.6	0
30	2295-PUB: Impaired First-Phase Insulin Secretion Predicts the Development of Hyperglycemia in a Human Model of Acute Beta-Cell Mass Reduction. Diabetes, 2020, 69, .	0.6	0
31	2090-P: Noradrenergic Stimulus as a Potential Inducer of Human ÃŸ-Cell Dedifferentiation. Diabetes, 2020, 69, .	0.6	0
32	2110-P: Correlation between Ex Vivo Islet Proteomic Analysis and In Vivo Secretory Function in Humans. Diabetes, 2020, 69, 2110-P.	0.6	0
33	134-OR: Effects of PCSK9 Inhibitors on Glucose Metabolism and ÃŸ-Cell Function in Humans. Diabetes, 2020, 69, 134-OR.	0.6	0
34	Identification of two novel LDLR variants by Next Generation Sequencing. Annali Dell'Istituto Superiore Di Sanita, 2020, 56, 122-127.	0.4	2
35	Potential cause-effect relationship between insulin autoimmune syndrome and alpha lipoic acid: Two case reports. Nutrition, 2019, 57, 1-4.	2.4	16
36	Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2019, 21, 471-477.	4.4	17

#	Article	IF	Citations
37	Sodiumâ€glucose coâ€transporter inhibitors: Medications that mimic fasting for cardiovascular prevention. Diabetes, Obesity and Metabolism, 2019, 21, 2211-2218.	4.4	14
38	Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2685-2694.	3.6	6
39	Î²-Cell Fate in Human Insulin Resistance and Type 2 Diabetes: A Perspective on Islet Plasticity. Diabetes, 2019, 68, 1121-1129.	0.6	87
40	Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovascular Diabetology, 2019, 18, 20.	6.8	101
41	Italian Titration Approach Study (ITAS) with insulin glargine 300ÂU/mL in insulin-naÃ¯ve type 2 diabetes: Design and population. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 496-503.	2.6	7
42	The Interplay between Immune System and Microbiota in Diabetes. Mediators of Inflammation, 2019, 2019, 1-10.	3.0	29
43	1212-P: Sotagliflozin Reduces Markers of Arterial Stiffness in T1D: Pooled Analysis from inTandem 1 and inTandem 2 Clinical Trials. Diabetes, 2019, 68, 1212-P.	0.6	1
44	Diabetes Secondary to Pancreatic Diseases. Endocrinology, 2019, , 1-17.	0.1	0
45	999-P: Liraglutide Treatment in Obese Diabetic Patients Modulates Gut Microbiota. Diabetes, 2019, 68, 999-P.	0.6	1
46	1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D. Diabetes, 2019, 68, .	0.6	0
47	1756-P: ÃŸ-Cell Glucose Sensitivity and Intrapancreatic Adipose Tissue as Predictors of Diabetes Onset. Diabetes, 2019, 68, .	0.6	4
48	Effect of Vitamin D Supplementation on Obesityâ€Induced Insulin Resistance: A Doubleâ€Blind, Randomized, Placeboâ€Controlled Trial. Obesity, 2018, 26, 651-657.	3.0	33
49	Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes, Obesity and Metabolism, 2018, 20, 1781-1786.	4.4	32
50	Management of diabetes in older adults. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 206-218.	2.6	47
51	FLâ€926â€16, a novel bioavailable carnosinaseâ€resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db/db mice. British Journal of Pharmacology, 2018, 175, 53-66.	5.4	32
52	Better glycaemic control and less hypoglycaemia with insulin glargine 300 <scp>U/mL</scp> vs glargine 100 <scp>U/mL</scp>: 1â€year patientâ€level metaâ€analysis of the <scp>EDITION</scp> clinical studies in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 541-548.	4.4	69
53	Diabetes Secondary to Pancreatic Diseases. Endocrinology, 2018, , 1-17.	0.1	0
54	Increased Î²-Cell Workload Modulates Proinsulin-to-Insulin Ratio in Humans. Diabetes, 2018, 67, 2389-2396.	0.6	37

#	Article	IF	Citations
55	Diabetes Secondary to Pancreatic Diseases. Endocrinology, 2018, , 523-539.	0.1	0
56	Insulin Resistance Impairs Cognitive Performance Even in Healthy Subjects at Risk for Diabetes Mellitus. Diabetes, 2018, 67, .	0.6	1
57	In Insulin-Resistant Subjects, Islet Functional Changes Might Represent an Attempt to Increase the Incretin Effect. Diabetes, 2018, 67, 1971-P.	0.6	0
58	Quantitative Proteomic Analysis on Human Isletsâ€"New Markers of Cellular and Metabolic Dysfunction. Diabetes, 2018, 67, .	0.6	0
59	Publish and perish. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1035-1036.	2.6	0
60	Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Design, Development and Therapy, 2017, Volume 11, 2905-2919.	4.3	67
61	Nuclear Export of FoxO1 Is Associated with ERK Signaling in Î²-Cells Lacking Insulin Receptors. Journal of Biological Chemistry, 2016, 291, 21485-21495.	3.4	20
62	Î²-Cell Glucose Sensitivity Is Linked to Insulin/Glucagon Bihormonal Cells in Nondiabetic Humans. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 470-475.	3.6	34
63	Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovascular Diabetology, 2015, 14, 142.	6.8	68
64	Welcome aboard. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 1-2.	2.6	1
65	Metabolic consequences of the occlusion of the main pancreatic duct with acrylic glue after pancreaticoduodenectomy. American Journal of Surgery, 2015, 210, 783-789.	1.8	15
66	HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH. PLoS ONE, 2014, 9, e97136.	2.5	76
67	Insulin Resistance Alters Islet Morphology in Nondiabetic Humans. Diabetes, 2014, 63, 994-1007.	0.6	152
68	IL-21 Is a Major Negative Regulator of IRF4-Dependent Lipolysis Affecting Tregs in Adipose Tissue and Systemic Insulin Sensitivity. Diabetes, 2014, 63, 2086-2096.	0.6	49
69	Peroxiredoxin 6, a Novel Player in the Pathogenesis of Diabetes. Diabetes, 2014, 63, 3210-3220.	0.6	103
70	Blockade of receptor activator of nuclear factor-ÎºB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nature Medicine, 2013, 19, 358-363.	30.7	211
71	Removal of Duodenum Elicits GLP-1 Secretion. Diabetes Care, 2013, 36, 1641-1646.	8.6	28
72	Genetic Disruption of SOD1 Gene Causes Glucose Intolerance and Impairs Î²-Cell Function. Diabetes, 2013, 62, 4201-4207.	0.6	34

#	Article	IF	Citations
73	Highâ€normal tsh values in obesity: Is it insulin resistance or adipose tissue's guilt?. Obesity, 2013, 21, 101-106.	3.0	65
74	A Rare Case of Ectopic Adrenocorticotropic Hormone Syndrome Caused by a Metastatic Neuroendocrine Tumor of the Pancreas Detected by 68Ga-DOTANOC and 18F-FDG PET/CT. Clinical Nuclear Medicine, 2013, 38, e306-e308.	1.3	16
75	Comment on: Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379. Diabetes Care, 2012, 35, e71-e71.	8.6	8
76	Evaluation of Guidelines on Diabetes Medication. Annals of Internal Medicine, 2012, 156, 752.	3.9	1
77	Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS?. Clinical Nutrition, 2012, 31, 476-480.	5.0	69
78	Self-Monitoring of Blood Glucose: Guideline Application Rather than Utilization Restrictions on Testing Strips Has Potential to Reduce Diabetes Healthcare Costs in Italy. Diabetes Technology and Therapeutics, 2012, 14, 862-867.	4.4	11
79	Vitamin D Deficiency: A New Risk Factor for Type 2 Diabetes. Annals of Nutrition and Metabolism, 2012, 61, 337-348.	1.9	97
80	Can vitamin D deficiency cause diabetes and cardiovascular diseases? Present evidence and future perspectives. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 81-87.	2.6	108
81	Dâ€carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a Western diet through reduction of carbonyl stress and inflammation. British Journal of Pharmacology, 2012, 166, 1344-1356.	5.4	72
82	Î²-Adrenergic Responsive Induction of Insulin Resistance in Liver of Aging Rats. Endocrine Research, 2011, 36, 74-82.	1.2	8
83	The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship?. Clinical Endocrinology, 2011, 74, 300-305.	2.4	38
84	In anorexia nervosa, even a small increase in abdominal fat is responsible for the appearance of insulin resistance. Clinical Endocrinology, 2011, 75, 202-206.	2.4	27
85	Metabolic Syndrome in Transplant Patients: An Academic or a Health Burden?. Transplantation Proceedings, 2011, 43, 313-317.	0.6	10
86	Singleâ€fiber conduction velocity test allows earlier detection of abnormalities in diabetes. Muscle and Nerve, 2011, 43, 652-656.	2.2	7
87	The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach. Current Diabetes Reviews, 2011, 7, 313-324.	1.3	293
88	Will vitamin D reduce insulin resistance? Still a long way to go. American Journal of Clinical Nutrition, 2011, 93, 672-673.	4.7	1
89	Association of Vitamin D With Insulin Resistance and Î²-Cell Dysfunction in Subjects at Risk for Type 2 Diabetes. Diabetes Care, 2010, 33, e99-e99.	8.6	5
90	25â€Hydroxyvitamin D Concentration Correlates With Insulinâ€Sensitivity and BMI in Obesity. Obesity, 2010, 18, 1906-1910.	3.0	122

#	Article	IF	Citations
91	Glucose toxicity: The leading actor in the pathogenesis and clinical history of type 2 diabetes â€“ mechanisms and potentials for treatment. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 365-377.	2.6	88
92	The Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) Is Associated With High GAD Antibody Titer in Latent Autoimmune Diabetes in Adults. Diabetes Care, 2008, 31, 534-538.	8.6	56
93	High Titer of Autoantibodies to GAD Identifies a Specific Phenotype of Adult-Onset Autoimmune Diabetes. Diabetes Care, 2007, 30, 932-938.	8.6	206
94	Phenotype modulation in cultures of vascular smooth muscle cells from diabetic rats: Association with increased nitric oxide synthase expression and superoxide anion generation. Journal of Cellular Physiology, 2003, 196, 378-385.	4.1	52
95	Lactate infusion to normal rats during hyperglycemia enhances in vivo muscle glycogen synthesis. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1997, 273, R2072-R2079.	1.8	7
96	Increased nonoxidative glucose metabolism in idiopathic reactive hypoglycemia. Metabolism: Clinical and Experimental, 1996, 45, 606-610.	3.4	16
97	Increased Insulin Sensitivity in Patients with Idiopathic Reactive Hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 1989, 69, 885-890.	3.6	54
98	Isocratic high-performance liquid chromatographic determination of the concentration and specific radioactivity of phosphoenolpyruvate and uridine disphosphate glucose in tissue extracts. Biomedical Applications, 1989, 497, 69-78.	1.7	31
99	High-Normal TSH Values in Obesity: Is It Insulin Resistance or Adipose Tissue's Guilt?. Obesity, 0, , .	3.0	2